Akorn Announces Submission of an ANDA Drug Product Developed Jointly with Sofgen Pharmaceuticals
BUFFALO GROVE, Ill.--Akorn, Inc. (NASDAQ:AKRX) today announced the submission of an ANDA drug product developed jointly with Sofgen Pharmaceuticals. Akorn is requesting an Expedited Review of the ANDA drug product, which is identical to the reference …